Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the
Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the radiopharmaceuticalsdivision of Du Pont Merck Pharmaceutical. He also held positionsat American Hospital Supply, where he developed an understandingof the injectable drug market, which will be key to marketingSonus' agents, according to the company.
Sonus, of Costa Mesa, CA, is developing intravenous ultrasoundcontrast agents based on a dodecafluoropentane-based emulsion.The company has filed an investigational new drug (IND) applicationwith the Food and Drug Administration for EchoGen, a cardiac contrastagent (SCAN 1/19/94).
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
Can Innovations with AI Help Address the Impact of Staffing Shortages on Radiology Workflow?
October 7th 2024While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.